Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

GHK vs Glow

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

GHK and Glow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

GHK

Preclinical + Cosmetic

Glow

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

GHK Glow
Class Matrikine tripeptide; signaling/reparative Three-component regenerative blend (matrikine + cytoprotective + actin-regulator)
Drug class Tissue Repair Tissue Repair
Mechanism Modulates expression of hundreds of genes related to tissue repair; copper transport Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate.
Route Topical / SC SC injection
Half-life Minutes (plasma) Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake)
Dosage (research) 1-5 mg daily topical/SC (research) Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution
Evidence tier Preclinical + Cosmetic Anecdotal
Research depth 163 indexed (PubMed 145 · CT 1 · EPMC 17) —
Availability Research Compounding Restricted
Reported risks Less bioavailable than GHK-Cu; limited injectable human trials No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick GHK or Glow?

GHK and Glow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.

What is the difference between GHK and Glow?

GHK is classed as Matrikine tripeptide; signaling/reparative; Glow is classed as Three-component regenerative blend (matrikine + cytoprotective + actin-regulator). Reported mechanism: GHK, Modulates expression of hundreds of genes related to tissue repair; copper transport; Glow, Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate. Reported half-life: GHK, Minutes (plasma); Glow, Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake). Routes in published studies: GHK, Topical / SC; Glow, SC injection.

Which has stronger evidence, GHK or Glow?

Glow has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK is graded Preclinical + Cosmetic, with 8 cited sources on its reference page and 163 indexed studies. Glow is graded Anecdotal, with 3 cited sources on its reference page.

Which is more accessible, GHK or Glow?

Neither GHK nor Glow is an FDA-approved drug. Catalog status: GHK, Research; Glow, Compounding Restricted.

Are GHK and Glow ever combined?

GHK and Glow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…